New cancer cell stress target that helps pancreatic cancer resist treatment
Official title: A Novel Cell Stress Response Mechanism in Pancreatic Cancer
Funded at University of Tx Md Anderson Can Ctr · NIH-11447066 · Data updated 2026-11-12
Researchers are studying a new stress-response mechanism in pancreatic cancer to find ways to make treatments more effective for people with this tough disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $633,089 |
| NIH project number | 1R01CA308198-01A1 |
| Project ID | NIH-11447066 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with pancreatic ductal adenocarcinoma whose disease is driven by stress-adapted tumor cells and immune interactions may benefit from future therapies targeting the identified mechanism.
✕Less likely to help
Early-stage basic discovery studies may not yet translate into direct benefits for patients in the near term.
What this research studies
Pancreatic cancer often survives standard therapies because its cells adapt to stressful conditions. This project uses a broad discovery platform to map how tumor cells and the immune system interact in the harsh pancreatic tumor environment. The team aims to identify a newly recognized stress regulator that helps cancer cells endure stress, evade immune attack, and persist. By understanding this mechanism, they hope to uncover targets for new therapies that could improve immune-based treatment strategies for PDAC.
Why it matters
Potential benefit: If successful, the work could lead to new therapeutic targets that make pancreatic cancer more vulnerable to treatment and potentially improve patient outcomes.
How similar studies have gone: Similar approaches identifying tumor-stromal and immune interactions have yielded actionable targets in other cancers, suggesting promise for this strategy in PDAC.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Yao, Wantong — University of Tx Md Anderson Can Ctr
- Study coordinator: Yao, Wantong
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.